Relmada Announces Failure of Phase III Study of REL-1017 for Major Depressive Disorder (MDD)
ADC评论
October 17, 2022
On October 13, Relmada Therapeutics announced that its REL-1017 for the treatment of major depressive disorder (MDD) failed to meet the primary endpoint of improvement
